Previous studies validated that the overexpression of LRH1 may induce the resistance of breast cancer to chemotherapy (12, 13), the metastasis of pancreas cancer (14), the poor prognosis of colon cancer (15) and non-small cell lung cancer (16), and the proliferation of hepatoblastoma (17). Here, NR5A2 is linked to pancreatic neoplasm.